Skip to main content
Narjust Florez, MD, and Stephanie McDonald, MSN, FNP-BC, AOCNP
Videos
09/10/2026
Narjust Florez, MD; Stephanie McDonald, MSN
Narjust Florez, MD, and Stephanie McDonald, MSN, FNP-BC, AOCNP, discuss key lung cancer findings from the 2026 ASCO Annual Meeting and their implications for oncology APPs. They review long-term CROWN data supporting first-line lorlatinib in...
Narjust Florez, MD, and Stephanie McDonald, MSN, FNP-BC, AOCNP, discuss key lung cancer findings from the 2026 ASCO Annual Meeting and their implications for oncology APPs. They review long-term CROWN data supporting first-line lorlatinib in...
Narjust Florez, MD, and...
09/10/2026
Oncology Learning Network APP Institute
Madeline Merrill, AGNP-BC, MSN
Videos
09/01/2026
Madeline Merrill, AGPCNP-BC, MSN
Madeline Merrill, AGNP-BC, MSN, discusses how oncology research can move from promising evidence to sustainable changes in clinical practice. Drawing on research presented at the 2026 ASCO Annual Meeting, Merrill highlights the importance of...
Madeline Merrill, AGNP-BC, MSN, discusses how oncology research can move from promising evidence to sustainable changes in clinical practice. Drawing on research presented at the 2026 ASCO Annual Meeting, Merrill highlights the importance of...
Madeline Merrill, AGNP-BC, MSN,...
09/01/2026
Oncology Learning Network APP Institute
Madeline Merrill, AGNP-BC, MSN
Videos
09/01/2026
Madeline Merrill, AGPCNP-BC, MSN
Madeline Merrill, AGNP-BC, MSN, discusses care delivery innovations highlighted at the 2026 ASCO Annual Meeting and their implications for oncology APPs. Merrill emphasizes that innovation extends beyond new drugs and technologies to changes...
Madeline Merrill, AGNP-BC, MSN, discusses care delivery innovations highlighted at the 2026 ASCO Annual Meeting and their implications for oncology APPs. Merrill emphasizes that innovation extends beyond new drugs and technologies to changes...
Madeline Merrill, AGNP-BC, MSN,...
09/01/2026
Oncology Learning Network APP Institute
Jasmin Hundal, MD, DipABLM, MS, MPH
Conference Coverage
08/06/2026
Jasmin Hundal, MD, DipABLM, MS, MPH
Jasmin Hundal, MD, DipABLM, MS, MPH, discusses how themes reinforced at the 2026 ASCO Annual Meeting are accelerating the use of digital health technologies that are reshaping oncology practice for advanced practice providers (APPs). She...
Jasmin Hundal, MD, DipABLM, MS, MPH, discusses how themes reinforced at the 2026 ASCO Annual Meeting are accelerating the use of digital health technologies that are reshaping oncology practice for advanced practice providers (APPs). She...
Jasmin Hundal, MD, DipABLM, MS,...
08/06/2026
Oncology Learning Network APP Institute
Jasmin Hundal, MD, DipABLM, MS, MPH
Conference Coverage
08/04/2026
Jasmin Hundal, MD, DipABLM, MS, MPH
Jasmin Hundal, MD, DipABLM, MS, MPH, discusses how artificial intelligence (AI) is becoming an increasingly practical tool for oncology advanced practice providers (APPs), reviewing current and emerging applications—including ambient...
Jasmin Hundal, MD, DipABLM, MS, MPH, discusses how artificial intelligence (AI) is becoming an increasingly practical tool for oncology advanced practice providers (APPs), reviewing current and emerging applications—including ambient...
Jasmin Hundal, MD, DipABLM, MS,...
08/04/2026
Oncology Learning Network APP Institute
David Spigel, MD, Sarah Cannon Research Institute
Videos
06/16/2025
David Spigel, MD
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the...
06/16/2025
Oncology Learning Network APP Institute
Patrick Forde, MBBCh
Videos
06/05/2025
Patrick Forde, MD
Patrick Forde, MBBCh, shares insights on the long-term overall survival benefit demonstrated by neoadjuvant nivolumab plus chemotherapy among patients with resectable non-small cell lung cancer, as seen in the CheckMate 816 trial.
Patrick Forde, MBBCh, shares insights on the long-term overall survival benefit demonstrated by neoadjuvant nivolumab plus chemotherapy among patients with resectable non-small cell lung cancer, as seen in the CheckMate 816 trial.
Patrick Forde, MBBCh, shares...
06/05/2025
Oncology Learning Network APP Institute